Pay ₹0 for 75 days of Genius, On India's 75 years of Independence by signing up within 75 hours
close-calc
 
 
Download Mobile Apps
close
Sucess

Great! You have sucessfully subscribed for newsletters for investments

Subscribed email:

刀塔2今晚比赛手机app

NAV as of ( Sep 09, 2022 )

302.85 -0.05 % 1-D Change

16.33% p.a.

You get upto 0.92% extra returns

ET Money's Fund Report Card - Nippon India Pharma Fund

ET Money Rank

not ranking
ranking

Not yet ranked

Performance Quality info

Very Good drop-arrow

Generated returns consistently

4/5

Increased returns for each unit of additional risk info

3/5

Downside Protection info

Good drop-arrow

Controlled losses during market corrections

3/5

Delivered returns without frequent ups and downs

3/5

Minimum SIP amount is ₹
Minimum Lumpsum amount is ₹

By continuing, I agree to the Declaration and T&Cs.

none buyable frame

Fresh Investments closed in this fund!

This fund is no longer available to invest

This fund vs
Show performance of:

Scheme Details

ET Money Rank Not yet ranked
VRO Rating N.A.
Expense ratio 1.06%  As on Jul 31, 2022
Exit Load 1.0% info
AUM (Fund Size) 4,588 Crs
Lock-in No Lockin
Age 9 yrs 8 m Since Jan 01, 2013
Benchmark S&P BSE Healthcare TRI
Min. Investment

SIP 100  &

Lumpsum 5000

About Nippon India Pharma Fund

Nippon India Pharma Fund Direct-Growth is a Sectoral-Pharma mutual fund scheme from Nippon India Mutual Fund . This fund has been in existence for 9 yrs 8 m, having been launched on 01/01/2013. Nippon India Pharma Fund Direct-Growth has ₹4,588 Crores worth of assets under management (AUM) as on 30/06/2022 and is medium-sized fund of its category. The fund has an expense ratio of 1.06%, which is close to what most other Sectoral-pharma funds charge.
  • Nippon India Pharma Fund Direct-Growth returns of last 1-year are -10.06%. Since launch, it has delivered 16.34% average annual returns. The fund has doubled the money invested in it every 3 yrs.
  • Nippon India Pharma Fund Direct-Growth scheme's ability to deliver returns consistently is in-line with most funds of its category. Its ability to control losses in a falling market is average.
  • The fund has the majority of its money invested in Healthcare sectors. It has taken less exposure in Healthcare sectors compared to other funds in the category.
  • The fund's top 5 holdings are in Sun Pharmaceutical Inds. Ltd., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd..
.....
Find your investor personality!

Answer a few simple questions and understand why you take the financial decisions you do.

Investment Returns Calculator

of for
Profit

You would have earned ₹ 1,001 more by investing in ET Money Direct Plan

Total value Profit
This fund
Category Average
Bank FD
Gold

Disclaimer: Products compared like fixed deposits may provide fixed guaranteed returns. Mutual Funds investments are subject to market risk, read all scheme related documents carefully. Past performance is not an indicator of future returns.

Latest Asset & Portfolio Allocation

as on Aug 31, 2022
Allocation by Market Cap

Large Cap 49.41%

Mid Cap 28.12%

Small Cap 22.15%

Other Cap 0%

Allocation by Sector

Healthcare 99.68%

Top Debt Holdings

Bifurcation by Holding is not available for this fund

Allocation by Credit Quality

Bifurcation by Credit Quality is not available for this fund

Allocation by Instruments

Repo 0.53%

Other Holdings

Others 0.53%

Know in detail about the portfolio of this fund See detailed Portfolio Analysis

Comparison with sectoral-pharma Funds

as on Sep 12, 2022
Average
0.52%
0.21 % p.a
This fund

Lowest
-0.1%

Highest
1.98%
Pick time period to see return
  • 1m
  • 3m
  • 6m
  • 1y
  • 3y
  • 5y
Fund name Annual Return % Consistency Value Research Rating
Nippon India Pharma Fund 18.29%
N.A.
Tata India Pharma & HealthCare Fund 16.85%
N.A.
UTI Healthcare Fund 13.95%
N.A.
SBI Healthcare Opportunities Fund 13.45%
N.A.

Trailing Returns and Ranks

as on Sep 12, 2022
Period Trailing returns Category average Rank within category
1 month 0.21% 0.53% 5 / 8
3 months 7.56% 7.78% 4 / 8
6 months -2% -1.62% 5 / 8
1 year -10.05% -9.71% 4 / 8
3 years 26.05% 25.82% 4 / 8
5 years 18.29% 15.64% 1 / 4

Know in detail about the returns of this fund See detailed Return Analysis

Riskometer

Level of Risk in the Scheme

Very High

Investors understand that their principal will be at Very High risk

Nippon India Pharma Fund

EQUITY SECTORAL-PHARMA

The scheme seeks to generate consistent returns by investing in equity / equity related or fixed income securities of pharma and other associated companies.

  • Std. Dev : 21.02
  • Alpha : 4.56
  • Beta : 0.92
  • Sharpe : 1.05
  • Sortino : 2.05
Nippon India Mutual Fund

Nippon India Mutual Fund

# SCHEMES

51

See all schemes

TOTAL AUM:

₹2,81,440 Crs

As on Jun 30, 2022

  • Phone: 1800-300-11111
  • Address: NG-1 & 1A, North Block
    Manipal Centre,Dickenson Road,

    Bangalore, 560042

Compare with similar Funds

Hide comparison

Frequently asked questions

How are the returns of Nippon India Pharma Fund ?

The Nippon India Pharma Fund is a 9 yrs 8 m old fund and has delivered average annual returns of 16.33% since inception.

Nippon India Pharma Fund Returns

1-Year 3-Year 5-Year Since Inception
-10.05% 26.05% 18.29% 16.33%

NAV or Net Asset Value is the per-unit price of the Mutual Fund. The NAV of a Mutual Fund changes every day. It is calculated by taking the current value of the holdings of the fund at end of the day, subtracting the expenses, and dividing the value by the number of units issued to date.

The NAV of Nippon India Pharma Fund for Sep 09, 2022 is 302.85 .

On ET Money, Investing in Nippon India Pharma Fund is fast, easy, and 100% paperless. And it takes only minutes. Here is what you need to do -

  1. Click on the Invest Now Button present on the top right-hand side.
  2. Enter your email id, select whether you want to do a one-time investment or start a SIP and add the amount
  3. Provide few more details needed including the bank account from which you will be making the payment and confirm.
  4. That's it. Your SIP or one-time investment in Nippon India Pharma Fund is done.

The Expense Ratio of a Mutual Fund is the annual charges you pay to the Mutual Fund company for managing your investments in that fund. The Expense Ratio is a percentage of Assets Under Management (AUM) and is taken from the returns generated by the fund. For this reason, a fund with a lower expense ratio is always better because a smaller part of the returns will be taken and that means more returns for you.

The Expense Ratio of the direct plan of Nippon India Pharma Fund is 1.06%.  .

Redeeming your investments in Nippon India Pharma Fund is super easy. If you have invested in this fund via ET Money, just login into the app, go to the investment section and put the redemption request.

If you have invested in Nippon India Pharma Fund from anywhere else, you can go to the fund house website and put a request through it.

AUM or Asset Under Management is the total value of the assets held by a Mutual Fund scheme. For instance, for an equity Mutual Fund, the AUM will be the total value of its portfolio's equity shares (plus any other asset it might have invested in). The AUM of the fund changes every day because the price of the underlying asset fluctuates daily. However, the Mutual Fund company doesn't update it every day. It is updated only at the end of the month and released within few days of the next month.

The AUM of the fund is a good indicator of its popularity. A fund with a high AUM means a lot of money has been invested in it, and investors like it. However, the AUM should never be the primary criteria while selecting a fund. There are funds with huge AUMs that continue to perform well despite their size.

The AUM of Nippon India Pharma Fund is ₹4,588 Crs.

The Nippon India Pharma Fund has invested the majority of its money in the stocks of the following companies -

Company Percentage of Portfolio
Sun Pharmaceutical Inds. Ltd. 14.21%
Cipla Ltd. 9.05%
Dr. Reddy's Laboratories Ltd. 7.87%
Lupin Ltd. 6.56%
Torrent Pharmaceuticals Ltd. 6.42%
Divi's Laboratories Ltd. 5.93%
Narayana Hrudayalaya Ltd. 5.64%
Abbott India Ltd. 5.28%
Aurobindo Pharma Ltd. 4.16%
Fortis Healthcare (India) Ltd 3.85%

The Nippon India Pharma Fund has primarily invested in the following sectors

Sector Percentage of Portfolio
Healthcare 99.68%
亚博电竞 csgo 日博电竞外围全球9.4.2 dota2投注线上 lpl电竞比分注册APP v2.6(lpl电竞选手下载v3.1版) JJ竞技(拉萨)登录手游